EASTON BIOPHARMACEUTICALS released its performance for the first three quarters, with a net profit attributable to the parent company of 220 million yuan, a year-on-year increase of 1.45%

Zhitong
2025.10.27 11:54
portai
I'm PortAI, I can summarize articles.

According to the Zhitong Finance APP, EASTON BIOPHARMACEUTICALS disclosed its third-quarter report for 2025. The company achieved revenue of 1.019 billion yuan in the first three quarters, a year-on-year decrease of 2%; net profit attributable to the parent company was 220 million yuan, a year-on-year increase of 1.45%; net profit excluding non-recurring items was 173 million yuan, a year-on-year increase of 3.10%; basic earnings per share were 1.25 yuan

According to the Zhitong Finance APP, EASTON BIOPHARMACEUTICALS (688513.SH) disclosed its third-quarter report for 2025. The company achieved revenue of 1.019 billion yuan in the first three quarters, a year-on-year decrease of 2%; the net profit attributable to the parent company was 220 million yuan, a year-on-year increase of 1.45%; the net profit excluding non-recurring gains and losses was 173 million yuan, a year-on-year increase of 3.10%; the basic earnings per share were 1.25 yuan

Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.